- Federal government must find alternatives to rescheduling hydrocodone combination drugs
- Actavis seeks approval for generic opioid-dependence drug
- FDA to recommend rescheduling of opioid painkiller hydrocodone from CIII to CII
- FDA issues sweeping new requirements for long-acting opioids
- Actavis launches generic version of Opana ER
PARSIPPANY, N.J. — The Food and Drug Administration has approved a drug for opioid dependence made by Actavis, the company said.
Actavis announced the approval of buprenorphine hydrochloride and naloxone hydrochloride dehydrate sub-lingual tablets in the 2 mg/0.5 mg and 8 mg/2 mg strengths.
The drug is a generic version of Reckitt Benckiser's Suboxone, which had sales of about $625 million in 2012, according to IMS Health.